Futuximab (992 DS) (INN) is a chimeric monoclonal antibody designed for the treatment of cancer.[1] It acts as an immunomodulator and also binds to HER1.[2][3]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (mouse/human) |
| Target | HER1 |
| Clinical data | |
| Other names | 992 DS |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C6468H10002N1724O2055S46 |
| Molar mass | 146269.94 g·mol−1 |
This drug was developed by Symphogen.
References
edit- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Futuximab, American Medical Association.
- ^ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).
- ^ Keir ST, Chandramohan V, Hemphill CD, Grandal MM, Melander MC, Pedersen MW, Horak ID, Kragh M, Desjardins A, Friedman HS, Bigner DD (July 2018). "Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models". J. Neurooncol. 138 (3): 489–498. doi:10.1007/s11060-018-2832-6. PMC 5999169. PMID 29564747.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |